Latest Development Funding News

Control Bionics Limited reported a 14.8% revenue increase to $6.14 million for FY2025 but also a 3.3% rise in net loss to $6.11 million, while pursuing a $2 million rights issue and expanding its investment portfolio.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Godolphin Resources is raising $3.03 million through a placement and entitlement offer to fast-track exploration and development at its Lewis Ponds Project in NSW, following a significant resource upgrade.

Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Pure Foods Tasmania has secured a $400,000 investment from entrepreneurs Jon Kontopos and Matthew Abrahams as part of a broader $750,000 capital raising effort, reinforcing confidence in the company’s turnaround plan ahead of its upcoming shareholder vote.

Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.

Opthea has successfully settled its Development Funding Agreement, avoiding a potential $680 million liability and securing $20 million in cash. Leadership changes include the CEO and CFO stepping down, with the Chairman assuming CEO duties.

Carbine Resources is set to issue over 110 million shares and broker options following shareholder approval, aiming to fund its Muchea and Down South Silica Sand projects and strengthen its working capital position.

Medallion Metals has amended terms to acquire 100% of Forrestania Nickel Operation assets, while progressing strong drilling results and financing discussions at Ravensthorpe Gold Project, positioning for a Final Investment Decision in late 2025.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.